SCOPE 2-Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography

被引：13

作者：

Bridges, S. ^{[1
]}

Thomas, B. ^{[2
]}

Radhakrishna, G. ^{[3
]}

Hawkins, M. ^{[4
]}

Holborow, A. ^{[5
]}

Hurt, C. ^{[1
]}

Mukherjee, S. ^{[6
]}

Nixon, L. ^{[1
]}

Crosby, T. ^{[2
]}

Gwynne, S. ^{[5
,7
]}

机构：

[1] Cardiff Univ, Ctr Trials Res, Cardiff, Wales

[2] Velindre Univ NHS Trust, Cardiff, Wales

[3] Christie NHS Fdn Trust, Manchester, Lancs, England

[4] UCL, Med Phys & Biomed Engn, London, England

[5] South West Wales Canc Ctr, Swansea, W Glam, Wales

[6] Univ Oxford, Oxford Inst Radiat Oncol, Oxford, England

[7] Swansea Univ, Med Sch, Swansea, W Glam, Wales

来源：

CLINICAL ONCOLOGY | 2022年 / 34卷 / 07期

关键词：

Dose escalation; radiotherapy; systemic therapy personalisation; oesophageal; PROTON-BEAM THERAPY; SIMULTANEOUS INTEGRATED BOOST; PREOPERATIVE CHEMORADIOTHERAPY; ESOPHAGOGASTRIC JUNCTION; METABOLIC-RESPONSE; CHEMOTHERAPY; RADIATION; CARCINOMA; PATTERNS; CARBOPLATIN/PACLITAXEL;

D O I：

10.1016/j.clon.2022.03.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The SCOPE 2 trial of definitive chemoradiotherapy in oesophageal cancer investigates the benefits of radiotherapy dose escalation and systemic therapy optimisation. The trial opened in 2016. The landscape of oesophageal cancer treatment over the lifetime of this trial has changed significantly and the protocol has evolved to reflect this. However, with the recent results of the Dutch phase III ART DECO study showing no improvement in local control or overall survival with radiotherapy dose escalation in a similar patient group, we sought to determine if the SCOPE 2 trial is still answering the key unanswered questions for oesophageal radiotherapy. Here we discuss the rationale behind the SCOPE 2 trial, outline the trial schema and review current data on dose escalation and outline recommendations for future areas of research. (C) 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

引用

页码：E269 / E280

页数：12

共 58 条

[51] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial [J].

Waddell, Tom ;

Chau, Ian ;

Cunningham, David ;

Gonzalez, David ;

Frances, Alicia ;

Okines, Clare ;

Wotherspoon, Andrew ;

Saffery, Claire ;

Middleton, Gary ;

Wadsley, Jonathan ;

Ferry, David ;

Mansoor, Wasat ;

Crosby, Tom ;

Coxon, Fareeda ;

Smith, David ;

Waters, Justin ;

Iveson, Timothy ;

Falk, Stephen ;

Slater, Sarah ;

Peckitt, Clare ;

Barbachano, Yolanda .

LANCET ONCOLOGY, 2013, 14 (06) :481-489

[52] A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer [J].

Wang, Henry ;

Ryu, Janice ;

Gandara, David ;

Bold, Richard J. ;

Urayama, Shiro ;

Tanaka, Michael ;

Goldberg, Zelanna ;

Follette, David ;

Narayan, Samir ;

Lau, Derick .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (02) :153-157

[53] Superiority of Deformable Image Co-registration in the Integration of Diagnostic Positron Emission Tomography-Computed Tomography to the Radiotherapy Treatment Planning Pathway for Oesophageal Carcinoma [J].

Ward, G. ;

Ramasamy, S. ;

Sykes, J. R. ;

Prestwich, R. ;

Chowdhury, F. ;

Scarsbrook, A. ;

Murray, P. ;

Harris, K. ;

Crellin, A. ;

Hatfield, P. ;

Sebag-Montefiore, D. ;

Spezi, E. ;

Crosby, T. ;

Radhakrishna, G. .

CLINICAL ONCOLOGY, 2016, 28 (10) :655-662

[54] Radiobiological Determination of Dose Escalation and Normal Tissue Toxicity in Definitive Chemoradiation Therapy for Esophageal Cancer [J].

Warren, Samantha ;

Partridge, Mike ;

Carrington, Rhys ;

Hurt, Chris ;

Crosby, Thomas ;

Hawkins, Maria A. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (02) :423-429

[55] QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy [J].

Weber, Damien C. ;

Tomsej, Milan ;

Melidis, Christos ;

Hurkmans, Coen W. .

RADIOTHERAPY AND ONCOLOGY, 2012, 105 (01) :4-8

[56] Failure patterns in patients with esophageal cancer treated with definitive chemoradiation [J].

Welsh, James ;

Settle, Stephen H. ;

Amini, Arya ;

Xiao, Lianchun ;

Suzuki, Akihiro ;

Hayashi, Yuki ;

Hofstetter, Wayne ;

Komaki, Ritsuko ;

Liao, Zhongxing ;

Ajani, Jaffer A. .

CANCER, 2012, 118 (10) :2632-2640

[57] Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageat junction [J].

Zhao, Kuai-Te ;

Liao, Zhongxing ;

Bucci, M. Kara ;

Komaki, Ritsuko ;

Cox, James D. ;

Yu, Zhiqian H. ;

Zhang, Lifei ;

Mohan, Radhe ;

Dong, Lei .

RADIOTHERAPY AND ONCOLOGY, 2007, 84 (03) :283-289

[58] 18F-FDG PET-Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial [J].

Zum Bueschenfelde, Christian Meyer ;

Herrmann, Ken ;

Schuster, Tibor ;

Geinitz, Hans ;

Langer, Rupert ;

Becker, Karin ;

Ott, Katja ;

Ebert, Matthias ;

Zimmermann, Frank ;

Friess, Helmut ;

Schwaiger, Markus ;

Peschel, Christian ;

Lordick, Florian ;

Krause, Bernd Joachim .

JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (08) :1189-1196

← 1 2 3 4 5 6 →